Catherine joined Ropes & Gray's corporate department in 2021. Catherine’s practice includes advising U.S. and international clients on highly complex strategic transactions involving technology, life sciences, branding and consumer products.
During law school, Catherine served as an editor for the Georgetown Journal of Law and Public Policy and drafted a white paper addressing the evolution of the Langdellian curriculum in U.S. law schools. She was named Georgetown’s Endowed Opportunity Scholar for all three years and was the recipient of a CALI award in International Business Negotiations.
Prior to law school, Catherine worked at a global research consulting company, where she co-authored reports to the U.S. Bureau of Justice Statistics on data visualization techniques involving the anatomy of sex trafficking networks in the Federal Justice System. She also served as a director at the Massachusetts Small Claims Advisory Service during her undergraduate years at Harvard.
Experience
- Advised ImmunoGen, Inc. on intellectual property matters related to its $10.1 billion sale to AbbVie Inc.
- Advised HUTCHMED (China) Limited in a $1.13 billion exclusive worldwide license to Takeda to develop, manufacture and commercialize HUTCHMED's colorectal cancer treatment, fruquintinib, outside of mainland China, Hong Kong and Macau. At signing, this was the largest deal in China history for small molecules discovered and developed by China biotechnology companies.
- Represented Regeneron Pharmaceuticals in its acquisition of 2seventy Bio Inc.’s platforms for the creation of new R&D cell medicines.
- Advised FB Debt Financing Guarantor, LLC and certain of its subsidiaries, a producer of luxury beauty brands, in their 363-sale transaction on issues relating to registered trademarks and other intellectual property licensing arrangements.
- Advised a Korea-based biotechnology company on material transfer agreements, licensing and collaboration matters.